Annexon, Inc. (ANNX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.00-7.51%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ANNX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
[TABLE] • | The ongoing, global, double masked Phase 3 ARCHER II trial remains on track, and all eligible patients have received at least 12 months of treatment, with masked event accrual consistent…
Stated in 2 of 2 supplied quarters. Management reported: “Vonaprument continues to be generally well-tolerated with a low discontinuation rate (<10%) and high compliance (>95%), reinforcing significant enthusiasm by physicians/patients.” “The ongoing proof-of-concept (POC) study is evaluating pharmacokinetics (PK) and pharmacodynamics (PD) in relation to food intake, and reduction in complement and bilirubin markers as a measure of hemolysis in patients with cold agglutinin disease (CAD).”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“[TABLE] • | The ongoing, global, double masked Phase 3 ARCHER II trial remains on track, and all eligible patients have received at least 12 months of treatment, with masked event accrual consistent…”
“• Next Milestone: Topline Phase 3 ARCHER II trial data expected in fourth quarter of 2026.”
[/TABLE] [TABLE] • | Next Milestone: Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.
Stated in 2 of 2 supplied quarters. Management reported: “Early outcomes reinforce the consistency and reproducibility of tanruprubart treatment effect previously demonstrated in Phase 3 and real-world evidence studies.” “Vonaprument continues to be generally well-tolerated with a low discontinuation rate (<10%) and high compliance (>95%), reinforcing significant enthusiasm by physicians/patients.”
“[/TABLE] [TABLE] • | Next Milestone: Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.”
“• Next Milestone: BLA submission with initial U.S./European data from FORWARD trial anticipated in 2026.”
Annexon’s current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.
Stated in 2 of 2 supplied quarters. Management reported: “Annexon’s current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.” “Annexon’s current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.”
“Annexon’s current cash, cash equivalents and short-term investments and funds from the credit facility are expected to fund operations and anticipated milestones into 2028.”
“Based on focused investments in its lead late-stage programs, Annexon expects to fund operations and anticipated milestones into the second half of 2027.”
The change in R&D expenses is primarily associated with the Phase 3 ARCHER II trial of vonaprument in GA and contract manufacturing expenses of our product candidates.
Stated in 2 of 2 supplied quarters. Management reported: “The change in R&D expenses is primarily associated with the Phase 3 ARCHER II trial of vonaprument in GA and contract manufacturing expenses of our product candidates.” “The change in G&A expenses reflects ongoing corporate consulting and professional services costs for the advancement of our registrational programs.”
“The change in R&D expenses is primarily associated with the Phase 3 ARCHER II trial of vonaprument in GA and contract manufacturing expenses of our product candidates.”
“The change in R&D expenses is primarily associated with the Phase 3 ARCHER II trial of vonaprument in GA, global regulatory filings of tanruprubart for GBS and contract manufacturing expenses of our…”
Focus on progressing pivotal Phase 3 trials for vonaprument and tanruprubart with key data readouts and regulatory submissions expected in 2026.
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.